

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effect of 3-in-1 block with bupivacaine 0.25% versus bupivacaine 0.25% plus 8 milligram dexamethasone in acute pain control of patients undergone hip nailing surgery

Protocol summary

khalediar@sums.ac.ir

Summary

The purpose of this randomized, double blinded clinical trial is to evaluate the effect of 3-in-1 block with bupivacaine 0.25% versus bupivacaine 0.25% plus 8 milligrams of dexamethasone in acute pain control of the patients undergoing elective hip nailing surgery. So we will randomly divide 44 ASA class I-III patients into two groups and depending on the group the patient will receive 3-in-1 block with bupivacaine 0.25% or bupivacaine 0.25% plus 8 milligrams of dexamethasone at the end of the surgery and we will measure post operative pain score with visual analog scale in certain periods of time during 24 hours post operation.

Recruitment status

Recruitment complete

Funding source

Shiraz University of Medical Sciences

Expected recruitment start date

2012-01-21, 1390/11/01

Expected recruitment end date

2012-04-18, 1391/01/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201201158728N1**

Registration date: **2012-02-25, 1390/12/06**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-02-25, 1390/12/06

Registrant information

Name

Afshin Amini

Name of organization / entity

Shiraz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 71 1623 5280

Email address

Scientific title

The effect of 3-in-1 block with bupivacaine 0.25% versus bupivacaine 0.25% plus 8 milligram dexamethasone in acute pain control of patients undergone hip nailing surgery

Public title

The effect of femoral block with bupivacaine in pain control of patients undergone hip nailing surgery

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Age: 50-80; ASA Class: I-III; Elective surgery. Exclusion criteria: Patients <50 or >80 years old; Weight >110 or <50; History of substance abuse and addiction; History of allergy to local anesthetics; Peripheral neuropathy; any neurologic deficit; Abnormal coagulation profile; Mental retardation; dementia; Inability to understand the pain score system.

Age

From **50 years** old to **80 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **44**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Shiraz University of Medical Sciences

Street address

Central building of Shiraz University of Medical Sciences, Zand street

City

Shiraz

Postal code

Approval date

2012-01-05, 1390/10/15

Ethics committee reference number

CT-90-1953

Health conditions studied

1

Description of health condition studied

Intertrochanteric fracture

ICD-10 code

S72.1

ICD-10 code description

Intertrochanteric fracture , Trochanteric fracture

Primary outcomes

1

Description

Pain

Timepoint

Hours of 0, 1/2 , 1, 6, 12, 24

Method of measurement

Visual analog scale

Secondary outcomes

1

Description

Failure of block

Timepoint

Hours of 0 and 1/2

Method of measurement

Presence of sense in the territory of 2 blocked nerves

2

Description

Nausea and/or vomiting

Timepoint

Hours of 0, 1/2 and 1

Method of measurement

Physician observation or patient complaint

3

Description

Arrhythmia and/or hypotension

Timepoint

Hours of 0, 1/2 and 1

Method of measurement

Monitoring the patient

4

Description

Hematoma

Timepoint

Hours of 0, 1/2, 1, 6, 12, 24

Method of measurement

Physician observation

Intervention groups

1

Description

For the control group: After approval of ethics committee, written and verbal consent will be obtained from the patients. All patients will be instructed on the 10 point visual analog scale. Anesthetic induction will be achieved with 0.03 mg/kg midazolam, 2 µ/kg fentanyl, 4-6 mg/kg thiopental and 0.5-0.6 mg/kg atracurium. For maintenance we will administer 1- 1.5 % Isoflurane and 50% N2O-50% O2 mixture. Remifentanil will be added (0.1-0.2 µg/kg/min) when there is an increase more than 30% from the baseline mean blood pressure or pulse during the surgery. At the end of surgery reversal will be administered for reversing muscle relaxation and before the patient is awake, with sufficient disinfection of the area, femoral 3-in-1 block will be performed by a physician blinded to study. The femoral nerve will be localized with the help of the peripheral nerve stimulator B|Braun. The presence of continuing contractions in the

quadriceps femoris muscle at a value of 0.5 mA is acceptable. While the needle is held in this position, 40 ml of 0.25% bupivacaine solution will be injected following a negative aspiration. The injection will be carried out within a period of two minutes with distal pressure application to increase the spread of the local anesthetic within the psoas sheath. After that the patient will be transferred to recovery with endotracheal tube and will be extubated in recovery room after awakening. The patients will be monitored for blood pressure, heart rate and O2 saturation for 1 hour and also they will be evaluated for any side effects such as nausea, vomiting, arrhythmia, decreased level of consciousness, hypotension and hematoma in the site of injection. Presence of sensory block in the femoral, obturator and lateral cutaneous nerve dermatomes will be tested with the pin-prick and if there is sense on the territory of 2 nerves the patient will be omitted from the study due to failure of block and another patient will be replaced. Pain score will be measured by visual analog scale (VAS) at the times of 0, 1/2, 1, 6, 12, and 24 (One hour after block is time 0) by a physician blinded to group of the patient. A VAS value of 3 will be accepted as an adequate level of analgesia. During the study if the patient develops VAS \geq 4, 2 milligrams of IV morphine will be administered slowly every half hour if necessary till it reaches below 4. Finally the patients will be asked to evaluate the general satisfaction of the pain treatment at the end of 24 hours (3=perfect, 2=good, 1=moderate and 0=bad).

Category

Treatment - Drugs

2

Description

For the intervention group: After approval of ethics committee, written and verbal consent will be obtained from the patients. All patients will be instructed on the 10 point visual analog scale. Anesthetic induction will be achieved with 0.03 mg/kg midazolam, 2 μ /kg fentanyl, 4-6 mg/kg thiopental and 0.5-0.6 mg/kg atracurium. For maintenance we will administer 1- 1.5 % Isoflurane and 50% N2O-50% O2 mixture. Remifentanil will be added (0.1-0.2 μ g/kg/min) when there is an increase more than 30% from the baseline mean blood pressure or pulse during the surgery. At the end of surgery reversal will be administered for reversing muscle relaxation and before the patient is awake, with sufficient disinfection of the area, femoral 3-in-1 block will be performed by a physician blinded to study. The femoral nerve will be localized with the help of the peripheral nerve stimulator B|Braun. The presence of continuing contractions in the quadriceps femoris muscle at a value of 0.5 mA is acceptable. While the needle is held in this position, 40 ml of 0.25% bupivacaine plus 8 milligrams of dexamethasone solution will be injected following a negative aspiration. The injection will be carried out within a period of two minutes with distal pressure application to increase the spread of the local anesthetic within the psoas sheath. After that the patient will be transferred to recovery with endotracheal tube and will be extubated in recovery room after awakening. The patients will be monitored for blood pressure, heart rate

and O2 saturation for 1 hour and also they will be evaluated for any side effects such as nausea, vomiting, arrhythmia, decreased level of consciousness, hypotension and hematoma in the site of injection. Presence of sensory block in the femoral, obturator and lateral cutaneous nerve dermatomes will be tested with the pin-prick and if there is sense on the territory of 2 nerves the patient will be omitted from the study due to failure of block and another patient will be replaced. Pain score will be measured by visual analog scale (VAS) at the times of 0, 1/2, 1, 6, 12, and 24 (One hour after block is time 0) by a physician blinded to group of the patient. A VAS value of 3 will be accepted as an adequate level of analgesia. During the study if the patient develops VAS \geq 4, 2 milligrams of IV morphine will be administered slowly every half hour if necessary till it reaches below 4. Finally the patients will be asked to evaluate the general satisfaction of the pain treatment at the end of 24 hours (3=perfect, 2=good, 1=moderate and 0=bad).

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Chamran Hospital

Full name of responsible person

Amin Reza Khaledi - Resident of anesthesiology and critical care

Street address

Chamran Boulevard

City

Shiraz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Afshin Amini M.D

Street address

Central building of Shiraz University of Medical Sciences, Zand street

City

Shiraz

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Postal code**Phone**

+98 71 1233 1549

Fax**Email**

aamini@sums.ac.ir;afshinaminie@yahoo.com

Web page address**Person responsible for general inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Amin Reza Khaledi M.D

Position

Resident of anesthesiology and critical care

Other areas of specialty/work**Street address**

Department of anesthesiology, Faghihi Hospital

City

Shiraz

Postal code**Phone**

+98 71 1623 5280

Fax**Email**

khalediar@sums.ac.ir;khaledi_amin@yahoo.com

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Amin Reza Khaledi M.D

Position

Resident of anesthesiology and critical care

Other areas of specialty/work**Street address**

Department of anesthesiology, Faghihi Hospital

City

Shiraz

Postal code**Phone**

+98 71 1623 5280

Fax**Email**

khalediar@sums.ac.ir;khaledi_amin@yahoo.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Afshin Amini M.D

Position

Assistant Professor of anesthesiology

Other areas of specialty/work**Street address**

Asateed-e Daneshgah Building, East Ghoddoosi boulevard

City

Shiraz

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty